Division of Health Services Research, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Center for Mental Healthcare and Outcomes Research, Central AR Veterans Healthcare System, Little Rock, AR, USA.
Addiction. 2020 Jun;115(6):1098-1112. doi: 10.1111/add.14940. Epub 2020 Jan 15.
To understand the potential harmful effects of dose escalation among patients with chronic, non-cancer pain (CNCP) on chronic opioid therapy.
Retrospective cohort study.
United States Veterans Healthcare Administration.
Veterans with CNCP and on chronic opioid therapy were identified using data from fiscal years 2008-15. The Veteran sample was approximately 90% male and 70% white.
Dose escalators [increase of > 20% average morphine milligram equivalent (MME) daily dose] were compared with dose maintainers (change of ±20% average MME daily dose). A composite measure of subsequent substance use disorders (SUDs: opioid, non-opioid and alcohol use disorders) and opioid-related adverse outcomes (AOs: accidents resulting in wounds/injuries, opioid-related and alcohol and non-opioid medication-related accidents and overdoses, self-inflicted injuries) as well as the individual SUDs and AOs was examined. The primary analyses were conducted among a 1 : 1 matched sample of escalators and maintainers matched on propensity score and index date. Propensity scores were generated using demographic characteristics, medical comorbidities, medication and health-care utilization characteristics. Subgroup analyses were conducted by quartile of the propensity score. Sensitivity analyses were conducted using adjusted logistic regression, logistic regression using stabilized inverse probability of treatment weighting (SIPTW) and instrumental variable (IV) models using geographic variation in opioid dose escalation as the IV.
There were 32 420 maintainers and 20 767 escalators resulting in 19 358 (93.2%) matched pairs. Composite AOs [odds ratio (OR) = 1.31, 95% confidence interval (CI) = 1.23, 1.40], composite SUDs (OR = 1.31, 95% CI = 1.22, 1.41) and individual SUD and AO subtypes were higher among dose escalators, except for opioid-related accidents and overdoses and violence-related injuries. Subgroup analyses within the propensity score quartiles found similar results. Sensitivity analyses with the adjusted and SIPTW logistic regressions found similar results to the primary analyses for all outcomes except for opioid-related accidents and overdoses, which were found to be significantly higher among escalators. Sensitivity analyses with IV models provided mixed results with SUDs and the individual types of AOs.
Escalating the opioid dose for those with chronic, non-cancer pain is associated with increased risks of substance use disorder and opioid-related adverse outcomes.
了解慢性非癌性疼痛(CNCP)患者慢性阿片类药物治疗中剂量升级的潜在有害影响。
回顾性队列研究。
美国退伍军人医疗保健管理局。
使用 2008-15 财年的数据确定了患有 CNCP 并接受慢性阿片类药物治疗的退伍军人。退伍军人样本中约 90%为男性,70%为白人。
将剂量升级者(平均吗啡毫克当量(MME)每日剂量增加>20%)与剂量维持者(平均 MME 每日剂量变化±20%)进行比较。随后使用复合指标评估物质使用障碍(SUD:阿片类、非阿片类和酒精使用障碍)和阿片类药物相关不良后果(AOs:导致伤口/伤害、阿片类药物相关和酒精及非阿片类药物相关事故和过量的事故、自我伤害)以及个别 SUD 和 AOs。主要分析是在根据倾向评分和索引日期对升级者和维持者进行 1:1 匹配的样本中进行的。使用人口统计学特征、合并症、药物和医疗保健利用特征来生成倾向评分。通过倾向评分四分位数进行亚组分析。使用调整后的逻辑回归、使用稳定逆概率治疗加权(SIPTW)的逻辑回归和使用阿片类药物剂量升级的地理差异作为 IV 的工具变量(IV)模型进行敏感性分析。
有 32420 名维持者和 20767 名升级者,共产生 19358 对(93.2%)匹配对。复合 AOs(比值比[OR] = 1.31,95%置信区间[CI] = 1.23,1.40)、复合 SUD(OR = 1.31,95% CI = 1.22,1.41)和个体 SUD 和 AO 亚型在剂量升级者中更高,除了阿片类药物相关事故和过量以及与暴力相关的伤害。在倾向评分四分位数内的亚组分析中发现了类似的结果。使用调整后的和 SIPTW 逻辑回归的敏感性分析结果与主要分析结果相似,除了阿片类药物相关事故和过量,这在升级者中明显更高。使用 IV 模型的敏感性分析结果显示,SUD 和个别类型的 AOs 结果不一致。
对于患有慢性非癌性疼痛的患者,增加阿片类药物剂量与物质使用障碍和阿片类药物相关不良后果的风险增加有关。